Notably, the two mouse signatures and their associated phenotype strengths were defined by the initiating loss of tumor suppression event, namely Trp53 mutation versus either Mdm2 amplification or Cdkn2a loss. The gene discussed is CDKN2A; the disease is neoplasm.